Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03424226 · ClinicalTrials.gov registry record · Phase 1
Sickness Evaluation at Altitude With Acetazolamide at Relative Dosages
A Phase 1 study of Acute Mountain Sickness, sponsored by Stanford University.
- Completed
- Registry status
- Phase 1
- Development phase
- 105
- Enrollment target
- 1
- Study location
NCT03424226 is a Phase 1 study of Acute Mountain Sickness that has completed, run by Stanford University. The registered enrollment target is 105 participants. The trial reports 1 study location across 1 state.
The verdict
NCT03424226, a Phase 1 study of Acute Mountain Sickness, has completed, sponsored by Stanford University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 105 participants
- Enrollment target
- 1
- Study location
Study Summary
This double blind randomized trial will compare acetazolamide taken the morning of ascent to acetazolamide taken the evening prior to ascent for the prevention of acute mountain sickness (AMS). The day of ascent dosing has not been studied as a powered primary outcome. The study population is hikers who are ascending at their own rate under their own power in a true hiking environment at the White Mountain Research Station, Owen Valley Lab (OVL) and Bancroft Station (BAR), Bancroft Peak, White Mountain, California
Conditions Studied
Interventions
- DRUG Acetazolamide
Study Locations (1)
California
- Stanford University - Stanford
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 105 participants |
| Start Date | 2018-08-04 |
| Est. Completion | 2018-09-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03424226
The ClinicalTrials.gov registry entry for NCT03424226 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 105 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Acute Mountain Sickness appearing as the primary indexed condition, and to 1 intervention - of which Acetazolamide is the first listed.
NCT03424226 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT03424226 about?
NCT03424226 is a clinical study titled "Sickness Evaluation at Altitude With Acetazolamide at Relative Dosages". This double blind randomized trial will compare acetazolamide taken the morning of ascent to acetazolamide taken the evening prior to ascent for the prevention of acute mountain sickness (AMS). The day of ascent dosing has not been studied as a powered primary outcome. The study population is hikers...
What is the current status of trial NCT03424226?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 105 participants. The study started on 2018-08-04. Estimated completion is 2018-09-30.
What conditions does trial NCT03424226 study?
This clinical trial studies the following conditions: Acute Mountain Sickness.
What interventions are being tested in trial NCT03424226?
The interventions under investigation include: Acetazolamide (DRUG).
Who is sponsoring clinical trial NCT03424226?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03424226 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Acute Mountain Sickness
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.